Rituximab for bone lymphoma [8]

Annals of Internal Medicine

Volumn 134, Issue 12, 2001, Pages 1156-1157

  Savage, D G ^a   Staron, R ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; BONE BIOPSY; BONE CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LETTER; NONHODGKIN LYMPHOMA; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; SYMPTOM;

EID: 0035912733     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-12-200106190-00032     Document Type: Letter

References (5)

1. Malignant lymphoma of bone
2. Long-term results of combined modality therapy in primary bone lymphomas
3. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
4. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
5. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy